Ding, Y et al. revealed that blocking the interaction between integrin αvβ3 and EDIL3 by Cilengitide improved the sensitivity of tumor tissues to paclitaxel and reversed the epithelial-mesenchymal transition (EMT) of paclitaxel-resistant tumors, reducing the probability of tumor resistance [78]. The gene discussed is EDIL3; the disease is neoplasm.